We propose that a combination immunomodulatory therapy blocking the PD-1–PD-L1 pathway coupled with therapy blocking the IL-10–IL-10Receptor (R) pathway will enhance type 1 T cell functions such as cytotoxicity and will shift the immunosuppressive environment in AML towards a type 1 immune-enhancing environment, removing tumor cells. This evidence concerns the gene IL10 and neoplasm.